Genomic Vision is a publicly-traded company on the Euronext regulated market in Paris
The clinical trial undertaken by Genomic Vision and Reims University Hospital to validate a new test for the early detection and treatment of cervical cancer was chosen for an oral presentation at the Eurogin Congress in Salzburg
Bagneux (France) – Genomic Vision (FR0011799907 – GV), DNA molecular combing specialist that develops tests for the diagnostics market and tools for the life sciences research market, today announces that the IDAHO clinical trial launched at the end of 2015 in France, which aims to validate the integration of the oncogenic, i.e. high-risk, human papillomavirus (HPV-HR) as an indicator of the severity of cervical lesions and the risk of developing cervical cancer, was presented by Professor Christine Clavel, project coordinator, via an oral presentation at the Eurogin (EUropean Research Organisation on Genital Infection and Neoplasia) Congress held in Salzburg, Austria, from June 15 to 18, 2016.
The integration of HPV-HR DNA in a host’s genome is considered to be a key stage in the progression of precancerous lesions into cancerous lesions in the cervix. The aim of this study is to determine whether the integration of HPV-HR DNA in patients’ genomes is a sufficient diagnostic (severity of lesions) and prognostic (risk of progression of lesions) indicator. Genomic Vision’s molecular combing technique is currently the only one that allows the frequency of the integration of high-risk HPV-HR to be detected, in a direct and high resolution manner.
The IDAHO clinical trial comprises two phases:
The first phase began in December 2015, and aims to show that the integration of HPV is a biomarker for diagnosing high-risk precancerous lesions that require appropriate treatment to be defined. The number of patients to be included in this study has been able to be reduced from 3,500 to 1,550 thanks to the new technical developments of the HPV test by molecular combing, which now detects 14 high-risk HPV instead of the initial 5.
During the second phase, women who test positive for HPV infection with no declared lesions or with low-grade lesions will be monitored for 3 years. This will make it possible to validate the integration of HPV DNA as a prognostic biomarker.
Professor Christine Clavel, molecular biologist in the Biopathology laboratory at Reims University Hospital, who presented the study at the conference, says: “This innovative approach should enable us to better understand the integration of high-risk HPV in the host’s genome, notably in terms of the frequency of the integration. Indeed, HPV infections being frequent but often temporary, current HPV tests are sensitive but not specific enough to detect high-grade lesions. Searching for new biomarkers, identifying among HPV-positive women those who will actually develop a precancerous lesion, remains crucial. If the results of this study are conclusive, we will then be able to consider viral integration to be an efficient diagnostic and prognostic tool enabling cervical cancer screening to be optimized and the best course of treatment for the patient to be determined.”
Upcoming financial publication
2016 half-year results, Tuesday, July 26, 2016* (before trading)
* indicative date, which may be subject to change
ABOUT THE REIMS UNIVERSITY HOSPITAL
In keeping with public service values, the Reims University Hospital (“Centre Hospitalier Universitaire de Reims”, or “CHU de Reims”) strives to meet one goal: to provide, through its 15 medical departments, excellent care and high-quality treatment to all patients in the Champagne-Ardenne region of France. The Reims University Hospital also works hard to maintain its positioning as a university hospital and to promote the involvement of its medical staff in innovative research projects. Professor Christine Clavel and Doctor Véronique Dalstein, molecular biologists in the Reims University Hospital’s Biopathology laboratory, headed by Professor Philippe Birembaut, have for many years been involved in research into HPV infections and use of the HPV test in clinical practice, notably in cervical cancer screening. This area of research is part of the Eastern France Cancer Research Cluster’s virus and cancer focus. Their research work in this field has received domestic and international acclaim.
For further information, please go to: www.chu-reims.fr
Genomic Vision: Aaron Bensimon Co-founder, Chairman & CEO Tel.: +33 1 49 08 07 50 email@example.com
NewCap Investor Relations / Strategic Communications Dušan Orešanský / Emmanuel Huynh Tel.: +33 1 44 71 94 92 firstname.lastname@example.org
LHA: Investor Relations US: Anne Marie Fields, SVP Tel.: 212-838-3777 email@example.com
Reims University Hospital: Julie Collin, PR Manager Tel.: +33 3 26 78 34 38 firstname.lastname@example.org
Member of CAC® Mid & Small, CAC® All-Tradable and EnterNext© PEA-PME 150 indexes
This press release contains certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the prospectus on which the French Financial Market Authority (AMF) granted its visa n° 14-087 on March 19, 2014 and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements. This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for GENOMIC VISION shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.